author-photo

Richard E. Clark

Royal Liverpool University Hospital
University of Liverpool

327

Papers

14608

Citations

Citation Trend

Filter By

Papers (327) Sort By

Journal Conference Others

Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia

2021
Show All
- Source
- Cite
- Save
Citations (0)
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (22)
Discovery of a Novel CIP2A Variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression.

2021 Blood Advances
Show All
- Source
- Cite
- Save
Citations (1)
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial.

2021 Haematologica
Show All
- Source
- Cite
- Save
Citations (0)
Ponatinib in Combination with FLAG-IDA Chemotherapy for Blast-Phase Chronic Myeloid Leukemia: Final Results of the Seamless Phase I/II Dose-Finding UK Trials Acceleration Programme (TAP) Matchpoint Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2)

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
Randomised evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients.

2021 Blood Advances
Show All
- Source
- Cite
- Save
Citations (0)
Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia.

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (0)